Want to see VNDA full AI Analyst Report?
VNDA Stock Chart & Stats
$5.44
$0.12(2.32%)
At close: 4:00 PM EDT
$5.44
$0.12(2.32%)
Day’s Range― - ―
52-Week Range$3.96 - $9.94
Previous CloseN/A
Volume13.12K
Average Volume (3M)1.03M
Market Cap
$242.46M
Enterprise Value$221.29M
Total Cash (Recent Filing)$170.03M
Total Debt (Recent Filing)$22.83M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Oct 28, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.63
Shares Outstanding60,462,690
10 Day Avg. Volume834,602
30 Day Avg. Volume1,034,287
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.59
Price to Sales (P/S)2.41
P/FCF Ratio-4.71
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue1.03
Enterprise Value/Gross Profit1.11
Enterprise Value/Ebitda-1.34
Forecast
1Y Price Target
$13.25Price Target Upside143.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-3.03
Revenue Forecast (FY)$248.84M
Bulls Say, Bears Say
Bulls Say
Fanapt Commercial MomentumFanapt is showing sustained demand growth across prescriptions and sales, including continued expansion after the bipolar I commercial rollout. This momentum supports a stronger commercial base, improves revenue visibility, and can help offset pressure from declining legacy products.
BYSANTI Protected Growth OpportunityBYSANTI adds an approved product with a planned second-half 2026 launch and long-dated regulatory and patent protection. If commercialization progresses as planned, the protected market position could support durable revenue growth and reduce reliance on older products.
Low Financial LeverageMinimal leverage reduces refinancing and solvency risk while preserving financial flexibility during the company’s product launches and development programs. A low-debt structure gives Vanda more capacity to manage operating volatility without the added burden of substantial interest obligations.
Bears Say
Deepening UnprofitabilityLosses are widening as operating expenses increase to support development and commercialization activities. Persistent unprofitability reduces internally generated funding, makes successful product execution more important, and could prolong pressure on equity and financial resources.
Ongoing Cash BurnSustained negative operating and free cash flow indicates that Vanda is not yet funding operations from its business activities. Higher expected cash burn increases dependence on revenue growth and expense moderation, leaving less flexibility if launches or pipeline programs underperform.
HETLIOZ Generic ErosionGeneric competition is materially reducing HETLIOZ revenue, weakening an established product’s contribution to the portfolio. Continued erosion raises the burden on Fanapt, BYSANTI, and pipeline products to replace lost sales and maintain overall commercial scale.
Vanda News
VNDA FAQ
What was Vanda Pharmaceuticals Inc.’s price range in the past 12 months?
Vanda Pharmaceuticals Inc. lowest stock price was $3.96 and its highest was $9.94 in the past 12 months.
What is Vanda Pharmaceuticals Inc.’s market cap?
Vanda Pharmaceuticals Inc.’s market cap is $242.46M.
When is Vanda Pharmaceuticals Inc.’s upcoming earnings report date?
Vanda Pharmaceuticals Inc.’s upcoming earnings report date is Oct 28, 2026 which is in 5 days.
How were Vanda Pharmaceuticals Inc.’s earnings last quarter?
Vanda Pharmaceuticals Inc. released its earnings results on Aug 05, 2026. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of -$0.582 by -$0.458.
Is Vanda Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Vanda Pharmaceuticals Inc.’s price is currently Undervalued.
Does Vanda Pharmaceuticals Inc. pay dividends?
Vanda Pharmaceuticals Inc. does not currently pay dividends.
What is Vanda Pharmaceuticals Inc.’s EPS estimate?
Vanda Pharmaceuticals Inc.’s EPS estimate is -0.68.
How many shares outstanding does Vanda Pharmaceuticals Inc. have?
Vanda Pharmaceuticals Inc. has 60,462,690 shares outstanding.
What happened to Vanda Pharmaceuticals Inc.’s price movement after its last earnings report?
Vanda Pharmaceuticals Inc. reported an EPS of -$1.04 in its last earnings report, missing expectations of -$0.582. Following the earnings report the stock price went up 0.491%.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in VNDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vanda Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.25 (143.57% Upside)
$13.25 (143.57% Upside)
Blogger Sentiment
Bullish
VNDA Sentiment 89%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 207.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.15%
12-Months-Change
Fundamentals
Return on Equity
-84.95%
Trailing 12-Months
Asset Growth
-33.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
VNDA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: multiple commercial and regulatory positives (strong Fanapt momentum, BYSANTI approval, NEREUS launch, imsidolimab BLA under review, several near-term phase 3 readouts, and reiterated 2026 revenue guidance implying growth) balanced against significant near-term financial pressures (larger net losses, sharply lower HETLIOZ sales due to generics, constrained NEREUS revenue recognition, increased operating expenses and reduced cash vs year-end 2025). Management expects operating expense moderation later in 2026 and into 2027 and believes existing resources plus anticipated revenues will fund operations through at least end of 2027, but execution risk on launches, trial readouts and revenue realization remain key uncertainties.View all VNDA earnings summariesVNDA Stock 12 Month Forecast
Average Price Target
$13.25
▲(143.57% Upside)
Technical Analysis
Ownership Overview
8.80% Insiders
13.86% Mutual Funds
0.09% Other Institutional Investors
59.49% Public Companies and
Individual Investors